{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:22:46Z","timestamp":1791393766527,"version":"4.3.3"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s40262-024-01442-8","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T13:34:37Z","timestamp":1736516077000},"page":"193-214","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical Pharmacokinetics of Antitubercular Drugs in the Overweight and Obese Population: Implications for Dosage Adjustments"],"prefix":"10.1007","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7326-8310","authenticated-orcid":false,"given":"Marlene","family":"Prager","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"al Jalali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Zeitlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"key":"1442_CR1","unstructured":"Lobstein T, Jackson-Leach R, Powis J, Brinsden H, Gray M. World Obesity Atlas 2023 [Internet]. World Obesity Federation. 2023. http:\/\/www.johnclarksondesign.co.uk"},{"key":"1442_CR2","unstructured":"World Health Organisation. Obesity and Overweight [Internet]. 2021. p. 1. http:\/\/www.who.int\/es\/news-room\/fact-sheets\/detail\/obesity-and-overweight."},{"key":"1442_CR3","unstructured":"World Health Organitation. Global Tuberculosis Report 2023 [Internet]. 2023. https:\/\/iris.who.int\/bitstream\/handle\/10665\/373828\/9789240083851-eng.pdf?sequence=1."},{"key":"1442_CR4","unstructured":"Avinash Kanchar, Dennis Falzon MZ. WHO: operational handbook on tuberculosis. Module 4: drug-susceptible tuberculosis treatment. Module 4: drug-susceptible tuberculosis treatment. 2022."},{"key":"1442_CR5","unstructured":"WHO. WHO: Operational handbook on tuberculosis. Module 4: drug-resistant tuberculosis treatment. WHO Press. 2022."},{"key":"1442_CR6","unstructured":"World Health Organization. WHO model list of essential medicines - 23nd list. World Heal Organ Geneva [Internet]. 2023;1\u201367. https:\/\/www.who.int\/publications\/i\/item\/WHO-MHP-HPS-EML-2023.01."},{"key":"1442_CR7","doi-asserted-by":"crossref","unstructured":"Lloret-Linares C, Mouly S, Hoang-Nguyen DT, Evans J, Raskine L, Lopes A, et al. Inadequate therapeutic response to a recommended antituberculosis fixed-dose combination regimen in an overweight patient with mycobacterium bovis infection. Ann Pharmacother. 2013;47(1).","DOI":"10.1345\/aph.1R452"},{"issue":"6","key":"1442_CR8","first-page":"944","volume":"131","author":"PJ Geiseler","year":"1985","unstructured":"Geiseler PJ, Manis RDJ, Maddux MS. Dosage of antituberculous drugs in obese patients. Am Rev Respir Dis. 1985;131(6):944\u20136.","journal-title":"Am Rev Respir Dis"},{"issue":"9","key":"1442_CR9","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1164\/rccm.201407-1264OC","volume":"191","author":"MJ Boeree","year":"2015","unstructured":"Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, et al. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med. 2015;191(9):1058\u201365.","journal-title":"Am J Respir Crit Care Med"},{"key":"1442_CR10","doi-asserted-by":"crossref","unstructured":"Peloquin CA, Vel\u00e1squez GE, Lecca L, Calder\u00f3n RI, Coit J, Milstein M, et al. Pharmacokinetic evidence from the HIRIF trial to support increased doses of rifampin for tuberculosis. Antimicrob Agents Chemother. 2017;61(8).","DOI":"10.1128\/AAC.00038-17"},{"key":"1442_CR11","doi-asserted-by":"crossref","unstructured":"Jindani A, Atwine D, Grint D, Bah B, Adams J, Ticona ER, et al. Four-month high-dose rifampicin regimens for pulmonary tuberculosis. NEJM Evid. 2023 Sep;2(9):EVIDoa2300054.","DOI":"10.1056\/EVIDoa2300054"},{"issue":"6","key":"1442_CR12","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2165\/00003088-197904060-00001","volume":"4","author":"WW Weber","year":"1979","unstructured":"Weber WW, Hein DW. Clinical pharmacokinetics of isoniazid. Clin Pharmacokinet. 1979;4(6):401\u201322.","journal-title":"Clin Pharmacokinet"},{"key":"1442_CR13","doi-asserted-by":"crossref","unstructured":"Drew RH. Ethambutol: an overview [Internet]. UpToDate. 2022. https:\/\/www.uptodate.com\/contents\/ethambutol-an-overview. Cited 18 Mar 2024.","DOI":"10.1097\/01.EEM.0001027844.53180.5d"},{"key":"1442_CR14","unstructured":"Drew RH, Sterling TR. Antituberculous drugs: an overview. UpToDate. 2024."},{"issue":"8","key":"1442_CR15","first-page":"967","volume":"12","author":"RE Hasenbosch","year":"2008","unstructured":"Hasenbosch RE, Alffenaar JWC, Koopmans SA, Kosterink JGW, van der Werf TS, van Altena R. Ethambutol-induced optical neuropathy: risk of overdosing in obese subjects. Int J Tuberc Lung Dis Off J Int Union Against Tuberc Lung Dis. 2008;12(8):967\u201371.","journal-title":"Int J Tuberc Lung Dis Off J Int Union Against Tuberc Lung Dis."},{"key":"1442_CR16","unstructured":"WHO. Companion handbook [Internet]. World Health Organization. 2014. http:\/\/apps.who.int\/iris\/bitstream\/10665\/75146\/1\/9789241548441_eng.pdf."},{"key":"1442_CR17","doi-asserted-by":"crossref","unstructured":"Drew RH. Pyrazinamide: An overview [Internet]. UpToDate. 2023. https:\/\/www.uptodate.com\/contents\/pyrazinamide-an-overview. Cited 19 Mar 2024.","DOI":"10.1097\/01.EEM.0000945444.32507.8c"},{"issue":"8","key":"1442_CR18","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","volume":"74","author":"A Alsultan","year":"2014","unstructured":"Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 2014;74(8):839\u201354.","journal-title":"Drugs"},{"key":"1442_CR19","doi-asserted-by":"publisher","unstructured":"Gouju J, Legeay S. Pharmacokinetics of obese adults: not only an increase in weight. Biomed Pharmacother [Internet]. 2023;166(August):115281. https:\/\/doi.org\/10.1016\/j.biopha.2023.115281.","DOI":"10.1016\/j.biopha.2023.115281"},{"key":"1442_CR20","doi-asserted-by":"crossref","unstructured":"Deshpande D, Pasipanodya JG, Mpagama SG, Bendet P, Srivastava S, Koeuth T, et al. Levofloxacin pharmacokinetics\/pharmacodynamics, dosing, susceptibility breakpoints, and artificial intelligence in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis Off Publ Infect Dis Soc Am. 2018;67(suppl_3):S293\u2013302.","DOI":"10.1093\/cid\/ciy611"},{"issue":"9","key":"1442_CR21","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1086\/424849","volume":"190","author":"T Gumbo","year":"2004","unstructured":"Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis. 2004;190(9):1642\u201351.","journal-title":"J Infect Dis"},{"issue":"7","key":"1442_CR22","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1128\/AAC.01680-10","volume":"55","author":"AM Cook","year":"2011","unstructured":"Cook AM, Martin C, Adams VR, Morehead RS. Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults. Antimicrob Agents Chemother. 2011;55(7):3240\u20133.","journal-title":"Antimicrob Agents Chemother"},{"key":"1442_CR23","doi-asserted-by":"crossref","unstructured":"Luque S, Grau S, Valle M, Colino CI, Ferrer A. Levofloxacin weight-adjusted dosing and pharmacokinetic disposition in a morbidly obese patient. Vol. 66. J Antimicrob Chemother Engl. 2011.1653\u20134.","DOI":"10.1093\/jac\/dkr146"},{"issue":"10","key":"1442_CR24","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1093\/jac\/dkr282","volume":"66","author":"MG Kees","year":"2011","unstructured":"Kees MG, Weber S, Kees F, Horbach T. Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients. J Antimicrob Chemother. 2011;66(10):2330\u20135.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"1442_CR25","doi-asserted-by":"publisher","first-page":"161","DOI":"10.18773\/austprescr.2021.035","volume":"44","author":"D Baggio","year":"2021","unstructured":"Baggio D, Ananda-Rajah MR. Fluoroquinolone antibiotics and adverse events. Aust Prescr. 2021;44(5):161\u20134.","journal-title":"Aust Prescr"},{"issue":"4","key":"1442_CR26","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s40264-018-0751-2","volume":"42","author":"E Gorelik","year":"2019","unstructured":"Gorelik E, Masarwa R, Perlman A, Rotshild V, Abbasi M, Muszkat M, et al. Fluoroquinolones and cardiovascular risk: a systematic review, meta-analysis and network meta-analysis. Drug Saf. 2019;42(4):529\u201338.","journal-title":"Drug Saf"},{"key":"1442_CR27","unstructured":"Medecins sans frontiers. Tuberculosis drug information sheets [Internet]. MSF medical guidelines. 2022. https:\/\/medicalguidelines.msf.org\/en\/viewport\/TUB\/english\/tuberculosis-drug-information-sheets-20323833.html. Cited 29 Mar 2024."},{"issue":"12","key":"1442_CR28","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1002\/psp4.12147","volume":"5","author":"EM Svensson","year":"2016","unstructured":"Svensson EM, Dosne A-G, Karlsson MO. Population pharmacokinetics of bedaquiline and metabolite M2 in patients with drug-resistant tuberculosis: the effect of time-varying weight and albumin. CPT Pharmacomet Syst Pharmacol. 2016;5(12):682\u201391.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"9","key":"1442_CR29","doi-asserted-by":"publisher","first-page":"5315","DOI":"10.1128\/AAC.01418-13","volume":"58","author":"SC McLeay","year":"2014","unstructured":"McLeay SC, Vis P, van Heeswijk RPG, Green B. Population pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drug. Antimicrob Agents Chemother. 2014;58(9):5315\u201324.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1442_CR30","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/jac\/dkaa550","volume":"76","author":"WA Alghamdi","year":"2021","unstructured":"Alghamdi WA, Al-Shaer MH, Kipiani M, Barbakadze K, Mikiashvili L, Kempker RR, et al. Pharmacokinetics of bedaquiline, delamanid and clofazimine in patients with multidrug-resistant tuberculosis. J Antimicrob Chemother. 2021;76(4):1019\u201324.","journal-title":"J Antimicrob Chemother"},{"key":"1442_CR31","unstructured":"Janssen Pharmaceutica NV. Sirturo, INN-bedaquiline- Summary of product characteristics [Internet]. 2014. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/sirturo-epar-product-information_en.pdf."},{"key":"1442_CR32","unstructured":"Bedaquiline\u202f: Drug information [Internet]. UpToDate. 2022. p. 1\u201323. https:\/\/www.uptodate.com\/contents\/bedaquiline-drug-information. Cited 21 Mar 2024."},{"issue":"11","key":"1442_CR33","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1093\/jac\/dkaa310","volume":"75","author":"MT Abdelwahab","year":"2020","unstructured":"Abdelwahab MT, Wasserman S, Brust JCM, Gandhi NR, Meintjes G, Everitt D, et al. Clofazimine pharmacokinetics in patients with TB: dosing implications. J Antimicrob Chemother. 2020;75(11):3269\u201377.","journal-title":"J Antimicrob Chemother"},{"key":"1442_CR34","doi-asserted-by":"crossref","unstructured":"Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, et al. Treatment of drug-resistant tuberculosis an official ATS\/CDC\/ERS\/IDSA clinical practice guideline. Vol. 200. Am J Respir Crit Care Med. 2019.","DOI":"10.1164\/rccm.201909-1874ST"},{"key":"1442_CR35","unstructured":"R-Pharm Germany GmbH. Deltyba, INN-Delamanid- Summary of product characteristics [Internet]. 2014. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/deltyba-epar-product-information_en.pdf."},{"key":"1442_CR36","unstructured":"Tuberculosis Expert Advisory Group. Guideline for the use of amikacin for drug resistant tuberculosis and nontuberculous mycobacterial infections in Queensland. 2021(March):1\u201311."},{"key":"1442_CR37","unstructured":"Mui E. Stanford Health Care Aminoglycoside Dosing Guideline. 2020;1\u20138. http:\/\/med.stanford.edu\/bugsanddrugs\/dosing-protocols\/_jcr_content\/main\/panel_builder\/panel_0\/download_2\/file.res\/AminoglycosideDosingGuide2017-08-23.pdf."},{"issue":"5","key":"1442_CR38","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/BF00542215","volume":"24","author":"LA Bauer","year":"1983","unstructured":"Bauer LA, Edwards WA, Dellinger EP, Simonowitz DA. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol. 1983;24(5):643\u20137.","journal-title":"Eur J Clin Pharmacol"},{"key":"1442_CR39","doi-asserted-by":"crossref","unstructured":"Nyang\u2019wa B-T, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, et al. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial. Lancet Respir Med. 2024;12(2):117\u201328.","DOI":"10.1016\/S2213-2600(23)00389-2"},{"issue":"10","key":"1442_CR40","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1901814","volume":"382","author":"F Conradie","year":"2020","unstructured":"Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020;382(10):893\u2013902.","journal-title":"N Engl J Med"},{"key":"1442_CR41","unstructured":"Lists WHOM, Medicines E, Fda US. Concept note dose optimization of rifampicin, isoniazid, pyrazinamide and ethambutol in the treatment of drug-susceptible tuberculosis 2. Recent WHO consultations and decisions made on optimizing dose of the first-line TB medicines. 2020;"},{"key":"1442_CR42","doi-asserted-by":"crossref","unstructured":"Simon P, Petroff D, Busse D, Heyne J, Girrbach F, Dietrich A, et al. Meropenem plasma and interstitial soft tissue concentrations in obese and nonobese patients-A controlled clinical trial. Antibiot (Basel, Switzerland). 2020;9(12).","DOI":"10.3390\/antibiotics9120931"},{"issue":"10","key":"1442_CR43","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1111\/jphp.12275","volume":"66","author":"SE Medell\u00edn-Garibay","year":"2014","unstructured":"Medell\u00edn-Garibay SE, Mil\u00e1n-Segovia RDC, Maga\u00f1a-Aquino M, Portales-P\u00e9rez DP, Romano-Moreno S. Pharmacokinetics of rifampicin in Mexican patients with tuberculosis and healthy volunteers. J Pharm Pharmacol. 2014;66(10):1421\u20138.","journal-title":"J Pharm Pharmacol"},{"key":"1442_CR44","doi-asserted-by":"crossref","unstructured":"Aarnoutse RE, AB, Kibiki GS, Reither CK, Semvua DEHH, Haraka CFF, Mtabho CM, Mpagama CSG, van den Boogaard GJ, CH, Sumari-de Boer IM, CI, Magis-Escurra CH, Wattenberg M, Logger JJGM, te Brake ALHM, ABH, et al. Pharmacokinetics, tolerability, and bacteriological response of rifampin administered at 600, 900, and 1,200 milligrams daily in patients with pulmonary tuberculosis. Antimicrob Agents Chemother. 2017;1\u201313.","DOI":"10.1128\/AAC.01054-17"},{"issue":"10","key":"1442_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0141002","volume":"10","author":"P Denti","year":"2015","unstructured":"Denti P, Jeremiah K, Chigutsa E, Faurholt-Jepsen D, PrayGod G, Range N, et al. Pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in newly diagnosed pulmonary TB patients in Tanzania. PLoS ONE. 2015;10(10):1\u201319.","journal-title":"PLoS ONE"},{"issue":"6","key":"1442_CR46","doi-asserted-by":"publisher","first-page":"627","DOI":"10.2165\/00003088-200544060-00004","volume":"44","author":"A S\u00e1nchez Navarro","year":"2005","unstructured":"S\u00e1nchez Navarro A, Colino Gandarillas C-I, Alvarez Lerma F, Menacho YA, Dom\u00ednguez-Gil A. Pharmacokinetics and pharmacodynamics of levofloxacin in intensive care patients. Clin Pharmacokinet. 2005;44(6):627\u201335.","journal-title":"Clin Pharmacokinet"},{"key":"1442_CR47","doi-asserted-by":"crossref","unstructured":"Hanretty AM, Moore WS 2nd, Chopra A, Cies JJ. Therapeutic drug monitoring of levoffoxacin in an obese adolescent: a case report. J Pediatr Pharmacol Ther United States. 2020;25:261\u20135.","DOI":"10.5863\/1551-6776-25.3.261"},{"issue":"3","key":"1442_CR48","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1128\/AAC.01036-07","volume":"52","author":"CA Peloquin","year":"2008","unstructured":"Peloquin CA, Hadad DJ, Molino LPD, Palaci M, Boom WH, Dietze R, et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother. 2008;52(3):852\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"1442_CR49","doi-asserted-by":"crossref","unstructured":"Peloquin CA, Phillips PPJ, Mitnick CD, Eisenach K, Patientia RF, Lecca L, et al. Increased doses lead to higher drug exposures of levofloxacin for treatment of tuberculosis. Antimicrob Agents Chemother. 2018;62(10).","DOI":"10.1128\/AAC.00770-18"},{"issue":"1","key":"1442_CR50","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/jac\/dkr436","volume":"67","author":"J De Smet","year":"2012","unstructured":"De Smet J, Colin P, De Paepe P, Ruige J, Batens H, Van Nieuwenhove Y, et al. Oral bioavailability of moxifloxacin after Roux-en-Y gastric bypass surgery. J Antimicrob Chemother. 2012;67(1):226\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"March","key":"1442_CR51","first-page":"1","volume":"14","author":"G Shao","year":"2023","unstructured":"Shao G, Bao Z, Davies Forsman L, Paues J, Werngren J, Niward K, et al. Population pharmacokinetics and model-based dosing evaluation of bedaquiline in multidrug-resistant tuberculosis patients. Front Pharmacol. 2023;14(March):1\u201312.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1442_CR52","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1345\/aph.1E484","volume":"39","author":"GE Stein","year":"2005","unstructured":"Stein GE, Schooley SL, Peloquin CA, Kak V, Havlichek DH, Citron DM, et al. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann Pharmacother. 2005;39(3):427\u201332.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"1442_CR53","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1128\/AAC.01453-12","volume":"57","author":"AA Bhalodi","year":"2013","unstructured":"Bhalodi AA, Papasavas PK, Tishler DS, Nicolau DP, Kuti JL. Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults. Antimicrob Agents Chemother. 2013;57(3):1144\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"1442_CR54","doi-asserted-by":"crossref","unstructured":"Blackman AL, Jarugula P, Nicolau DP, Chui SH, Joshi M, Heil EL, et al. Evaluation of linezolid pharmacokinetics in critically ill obese patients with severe skin and soft tissue infections. Antimicrob Agents Chemother. 2021;65(2).","DOI":"10.1128\/AAC.01619-20"},{"key":"1442_CR55","doi-asserted-by":"crossref","unstructured":"Mersfelder TL, Smith CL. Linezolid pharmacokinetics in an obese patient. Am J Health Syst Pharm. 2005;62:464 (467).","DOI":"10.1093\/ajhp\/62.5.464a"},{"issue":"3","key":"1442_CR56","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/jac\/dks431","volume":"68","author":"R Hamilton","year":"2013","unstructured":"Hamilton R, Thai XC, Ameri D, Pai MP. Oral bioavailability of linezolid before and after Roux-en-Y gastric bypass surgery: is dose modification necessary in obese subjects? J Antimicrob Chemother. 2013;68(3):666\u201373.","journal-title":"J Antimicrob Chemother"},{"key":"1442_CR57","doi-asserted-by":"crossref","unstructured":"Corcione S, Pagani N, Baietto L, Fanelli V, Urbino R, Ranieri VM, et al. Pharmacokinetics of high dosage of linezolid in two morbidly obese patients. J Antimicrob Chem Engl. 2015;70:2925.","DOI":"10.1093\/jac\/dkv238"},{"issue":"1","key":"1442_CR58","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00134-014-3550-y","volume":"41","author":"G De Pascale","year":"2015","unstructured":"De Pascale G, Fortuna S, Tumbarello M, Cutuli SL, Vallecoccia M, Spanu T, et al. Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration. Intensive Care Med. 2015;41(1):103\u201310.","journal-title":"Intensive Care Med"},{"key":"1442_CR59","doi-asserted-by":"crossref","unstructured":"Simon P, Busse D, Petroff D, Dorn C, Ehmann L, Hochst\u00e4dt S, et al. Linezolid concentrations in plasma and subcutaneous tissue are reduced in obese patients, resulting in a higher risk of underdosing in critically ill patients: a controlled clinical pharmacokinetic study. J Clin Med. 2020;9(4).","DOI":"10.3390\/jcm9041067"},{"key":"1442_CR60","doi-asserted-by":"crossref","unstructured":"Diacon AH, De Jager VR, Dawson R, Narunsky K, Vanker N, Burger DA, et al. Fourteen-day bactericidal activity, safety, and pharmacokinetics of linezolid in adults with drug-sensitive pulmonary tuberculosis. Antimicrob Agents Chemother. 2020;64(4).","DOI":"10.1128\/AAC.02012-19"},{"issue":"9","key":"1442_CR61","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1111\/bcp.13975","volume":"85","author":"M Mulubwa","year":"2019","unstructured":"Mulubwa M, Mugabo P. Steady-state population pharmacokinetics of terizidone and its metabolite cycloserine in patients with drug-resistant tuberculosis. Br J Clin Pharmacol. 2019;85(9):1946\u201356.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1442_CR62","doi-asserted-by":"publisher","first-page":"30","DOI":"10.5588\/ijtld.17.0475","volume":"22","author":"R Court","year":"2018","unstructured":"Court R, Wiesner L, Stewart A, de Vries N, Harding J, Maartens G, et al. Steady state pharmacokinetics of cycloserine in patients on terizidone for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis Off J Int Union Against Tuberc Lung Dis. 2018;22(1):30\u20133.","journal-title":"Int J Tuberc Lung Dis Off J Int Union Against Tuberc Lung Dis."},{"issue":"8","key":"1442_CR63","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s40262-022-01133-2","volume":"61","author":"L Tanneau","year":"2022","unstructured":"Tanneau L, Karlsson MO, Diacon AH, Shenje J, De Los RJ, Wiesner L, et al. Population pharmacokinetics of delamanid and its main metabolite DM-6705 in drug-resistant tuberculosis patients receiving delamanid alone or coadministered with bedaquiline. Clin Pharmacokinet. 2022;61(8):1177\u201385.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1442_CR64","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/jcph.196","volume":"54","author":"SC Cheatham","year":"2014","unstructured":"Cheatham SC, Fleming MR, Healy DP, Chung EK, Shea KM, Humphrey ML, et al. Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese patients hospitalized in an intensive care unit. J Clin Pharmacol. 2014;54(3):324\u201330.","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"1442_CR65","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1164\/rccm.202108-1976OC","volume":"205","author":"V De Jager","year":"2022","unstructured":"De Jager V, Gupte N, Nunes S, Barnes GL, van Wijk RC, Mostert J, et al. Early bactericidal activity of meropenem plus clavulanate (with or without rifampin) for tuberculosis: the COMRADE randomized, phase 2A clinical trial. Am J Respir Crit Care Med. 2022;205(10):1228\u201335.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"1442_CR66","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1592\/phco.21.13.1037.34625","volume":"21","author":"M Zhu","year":"2001","unstructured":"Zhu M, Burman WJ, Jaresko GS, Berning SE, Jelliffe RW, Peloquin CA. Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis. Pharmacotherapy. 2001;21(9):1037\u201345.","journal-title":"Pharmacotherapy"},{"issue":"10","key":"1442_CR67","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1111\/bcp.14795","volume":"87","author":"P Mugabo","year":"2021","unstructured":"Mugabo P, Mulubwa M. Ethionamide population pharmacokinetics\/pharmacodynamics and therapeutic implications in South African adult patients with drug-resistant tuberculosis. Br J Clin Pharmacol. 2021;87(10):3863\u201370.","journal-title":"Br J Clin Pharmacol"},{"issue":"2\u20133","key":"1442_CR68","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1054\/tube.2002.0330","volume":"82","author":"M Zhu","year":"2002","unstructured":"Zhu M, Namdar R, Stambaugh JJ, Starke JR, Bulpitt AE, Berning SE, et al. Population pharmacokinetics of ethionamide in patients with tuberculosis. Tuberculosis (Edinb). 2002;82(2\u20133):91\u20136.","journal-title":"Tuberculosis (Edinb)"},{"issue":"8","key":"1442_CR69","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1128\/AAC.01354-09","volume":"54","author":"AH Diacon","year":"2010","unstructured":"Diacon AH, Dawson R, Hanekom M, Narunsky K, Maritz SJ, Venter A, et al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother. 2010;54(8):3402\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"1442_CR70","doi-asserted-by":"crossref","unstructured":"Lyons MA. Modeling and simulation of pretomanid pharmacokinetics in pulmonary tuberculosis patients. Antimicrob Agents Chemother. 2018;62(7).","DOI":"10.1128\/AAC.02359-17"},{"key":"1442_CR71","doi-asserted-by":"publisher","unstructured":"McCarron MM, Devine BJ. Clinical pharmacy: case studies: case number 25 gentamicin therapy. Drug Intell Clin Pharm [Internet]. 1974;8(11):650\u20135. https:\/\/doi.org\/10.1177\/106002807400801104.","DOI":"10.1177\/106002807400801104"},{"key":"1442_CR72","unstructured":"Pai DM. Ideal body weight and adjusted body weight [Internet]. https:\/\/www.mdcalc.com\/calc\/68\/ideal-body-weight-adjusted-body-weight. Cited 21 May 2024."},{"issue":"10","key":"1442_CR73","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","volume":"44","author":"S Janmahasatian","year":"2005","unstructured":"Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051\u201365.","journal-title":"Clin Pharmacokinet"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01442-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-024-01442-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01442-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T16:48:04Z","timestamp":1738255684000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-024-01442-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1442"],"URL":"https:\/\/doi.org\/10.1007\/s40262-024-01442-8","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,10]]},"assertion":[{"value":"21 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Medical University of Vienna. No sources of funding were used to assist with the preparation\nof this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors do not have any conflict of interest directly relevant to the content of this review. Markus Zeitlinger is an Editorial Board member of Clinical Pharmacokinetics. Markus Zeitlinger was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Marlene Prager, Valentin al Jalali, and Markus Zeitlinger contributed to the concept and writing of the paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author's Contributions"}},{"value":"Not applicable. This review article does not involve any primary data collection from human participants.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable. The data used in this review is sourced from publicly available literature.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable. This review does not involve the use of any software code that requires sharing.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}